Weekly Recap | Summit Therapeutics +5.74%, ivonescimab data stack up
I'm LongbridgeAI, I can summarize articles.Summit Therapeutics (SMMT) gained 5.74% this week to close at $15.47, while the S&P 500 fell 0.47%, leaving the stock ahead of the benchmark by about 6.21 percentage points. The week opened at $14.90, ran up to an intraday high of $16.35 on Tuesday, then faded over the second half and settled into a narrow range. The latest close sits near the 60-day average of $15.49 and below the 20-day average of $16.29. Weekly amplitude was 10.2%.
The Week
Summit Therapeutics (SMMT) gained 5.74% this week to close at $15.47, while the S&P 500 fell 0.47%, leaving the stock ahead of the benchmark by about 6.21 percentage points. The week opened at $14.90, ran up to an intraday high of $16.35 on Tuesday, then faded over the second half and settled into a narrow range. The latest close sits near the 60-day average of $15.49 and below the 20-day average of $16.29. Weekly amplitude was 10.2%.
Key Events
Summit pushed forward its ivonescimab clinical pipeline through much of the week. On Monday it opened a global Phase II study of ivonescimab-based regimens in advanced clear cell renal cell carcinoma. On Wednesday the company entered a Phase II/III collaboration with ECOG-ACRIN to evaluate ivonescimab in first-line biliary tract cancer. On Thursday it said ivonescimab met the primary endpoint in a Phase II endometrial cancer study. On Friday Summit agreed with Lunit to apply the AI-powered SCOPE IO platform for tumour microenvironment analysis in immuno-oncology development.
Analyst Ratings
As of 23 October, 17 brokers cover the stock: 10 rate it buy, 1 overweight, and 6 hold, with no underweight or sell ratings. The consensus recommendation is buy, and the consensus target of $30.18 stands about 95.1% above the spot price of $15.47. Targets range from $11.997 to $43.584, a wide spread. Among 511 biotechnology companies, Summit ranks 40th in analyst rating.
The Week Ahead
Summit reports fiscal Q3 2026 results after the close next Tuesday, 27 October; estimates are for a loss of $0.2738 per share and revenue of $71.6k. The same day brings US durable goods orders, new home sales and consumer confidence data. The company’s full-year 2026 report is scheduled after the close on 23 February 2027.
In Short
The week’s tension was straightforward: rapid clinical progress drove SMMT ahead of the market, and the consensus target sits well above spot; yet the company has no positive P/E and a price-to-book near 19.59x, while volume ran slightly below its median. What matters next is whether the Q3 print and the pipeline keep supporting the current price.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.